Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
29 August 2022 |
Main ID: |
NCT03025542 |
Date of registration:
|
17/01/2017 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis
|
Scientific title:
|
A Multicenter, Randomized, Subject-Blind, Investigator-Blind Study to Evaluate the Time Course of Pharmacodynamic Response, Safety and Pharmacokinetics of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis |
Date of first enrolment:
|
December 2016 |
Target sample size:
|
49 |
Recruitment status: |
Completed |
URL:
|
https://clinicaltrials.gov/show/NCT03025542 |
Study type:
|
Interventional |
Study design:
|
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
|
Phase:
|
Phase 2
|
|
Countries of recruitment
|
Australia
|
Canada
|
Germany
|
Moldova, Republic of
|
United States
| | | |
Contacts
|
Name:
|
UCB Cares |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
+1 844 599 2273(UCB) |
| | |
Key inclusion & exclusion criteria
|
Health Condition(s) or Problem(s) studied
|
Source(s) of Monetary Support
|
|